Sacramento,
California
95817
Purpose:
The purpose of this study is to determine the safety and effectiveness of combination
therapy with Proleukin and Rituxan on patients with intermediate-and high- grade
Non-Hodgkin's lymphoma.
Criteria:
Inclusion:
- Diagnosis: CD20+ B-cell non-Hodgkin's lymphoma (NHL) classified as intermediate- or
high-grade according to the Working Formulation, subtypes D to H. Must have
measureable progressive or refractory disease after no more than three prior
chemotherapy regimens.
Exclusion:
- Clinically significant cardiac dysfunction, or a history of myocardial infarction or
heart failure within 6 months of first study treatment
- Clinically significant pulmonary dysfunction.
- Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no
active disease as demonstrated by undetectable HCV viral loads, biopsy showing no
active disease, and/or history of normal transaminases on at least three different
dates within one year of first study treatment).
- Symptomatic thyroid disease requiring medical intervention other than replacement
treatment for hypothyroidism.
- History of autoimmune disease.
- History of positive serology for human immunodeficiency virus (HIV).